SeaStar Medical to Present at Major Investor Conference
SeaStar Medical Holding Corporation (Nasdaq: ICU), a prominent player in the healthcare sector, is set to present at NobleCon21 - the Twenty First Annual Emerging Growth Equity Conference hosted by Noble Capital Markets. This event will hold at Florida Atlantic University within the Executive Education Complex.
Details of the Presentation
During the conference, Eric Schlorff, the Chief Executive Officer of SeaStar Medical, will take the stage to discuss the company's innovative therapies aimed at patients facing critical health challenges due to organ failure. The presentation is scheduled for a time slot that caters to investors eager to explore the company’s advancements in healthcare.
Revolutionizing Treatments for Critical Illness
SeaStar Medical is committed to transforming how critically ill patients are treated, especially those dealing with severe organ failure. Their pioneering QUELIMMUNE (SCD-PED) therapy marks a notable achievement in this journey. This cutting-edge therapy is based on the company’s patented Selective Cytopheretic Device (SCD) technology. Since its FDA approval, it has garnered attention as a breakthrough treatment for life-threatening acute kidney injury (AKI) stemming from sepsis, specifically in critically ill pediatric patients.
Importance of QUELIMMUNE Therapy
The QUELIMMUNE therapy stands out as the only FDA-approved option for treating this ultra-rare condition, and its significance cannot be overstated. By targeting severe health crises effectively, SeaStar Medical is paving the way for enhanced survival rates and improved quality of life for patients who have few, if any, effective treatments available.
Future Prospects and Innovations
In addition to its groundbreaking pediatric treatments, SeaStar Medical is actively conducting pivotal trials of its SCD therapy for adult patients suffering from AKI. This condition is particularly serious, affecting over 200,000 adults in the U.S. annually, and the potential to offer a solution is both promising and necessary.
Encouraging FDA Recognition
The Selective Cytopheretic Device (SCD) therapy, designed to address multiple therapeutic indications, has received the FDA’s Breakthrough Device Designation. This designation is significant as it facilitates expedited approval processes and opens doors for favorable reimbursement dynamics, ensuring that patients can access vital treatments swiftly.
Engagement with Investors
For those interested in learning more about SeaStar Medical's endeavors and the impact of its innovative treatments, attendance at NobleCon21 is encouraged. This gathering presents a unique opportunity for investors to gain insights directly from the executives leading this transformative company.
Accessing the Presentation Replay
For individuals who cannot attend the live presentation, a recording will be available for viewing after the event, allowing anyone to stay informed about SeaStar Medical's progress. Following the event, the replay will be accessible for 30 days, offering comprehensive insights into the company’s initiatives.
About SeaStar Medical
SeaStar Medical stands at the forefront of healthcare innovation. Their mission revolves around improving treatments for critically ill patients, significantly enhancing their chances of recovery and survival. The success of their QUELIMMUNE (SCD-PED) therapy exemplifies their dedication to using advanced technology to tackle pressing medical challenges.
Contact Information for Inquiries
Individuals wishing to reach out for more information can contact SeaStar Medical’s investor relations team via email. This contact point serves as a gateway for stakeholders eager to engage with the company directly regarding its future and ongoing research.
Frequently Asked Questions
What is SeaStar Medical's main focus?
SeaStar Medical primarily focuses on developing transformative treatments for critically ill patients dealing with organ failure.
What is QUELIMMUNE therapy?
QUELIMMUNE is SeaStar Medical's first commercial product, approved by the FDA to treat life-threatening acute kidney injury in critically ill pediatric patients.
Where will SeaStar Medical present its findings?
SeaStar Medical will present at the NobleCon21 conference held at Florida Atlantic University.
How can investors view the presentation replay?
Investors can view a replay of the presentation on SeaStar Medical's website 30 days following the conference.
What recent achievements has SeaStar Medical made?
The company has achieved FDA approval for its QUELIMMUNE therapy and received Breakthrough Device Designation for several therapeutic indications.
